Evidence Archives

MammaPrint^® Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2 breast cancer in NBRST

Publication: ASCO 2023, Abstract #521 Authors: Peter D. Beitsch 1 , James V. Pellicane 2 , Lajos Pusztai 3 , Paul L. Baron 4 , Erin F. Cobain 5 , Mary K. Murray 6 , Andrew Ashikari 7 , Pond R. Kelemen 7 , Angela Marie Mislowsky 8 , Julie Barone 9 , Kenneth H. Cowan 10 , Rakhshanda Layeequr Rahman 11 , William C. Dooley 12 , Andrea Menicucci 13 , Christine Carruth 13 , M. William Audeh 13 , Pat W. Whitworth 14 , NBRST Investigators Group

Read More

Joel Adamich2024-02-16T06:58:05-08:00June 18th, 2023|Evidence, NBRST, Neoadjuvant|

FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols

Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.

Read More

Joel Adamich2024-03-07T10:46:06-08:00June 18th, 2023|Evidence, FLEX TIPS, Other|

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.

Read More

Joel Adamich2024-03-07T10:44:18-08:00June 18th, 2023|Evidence, HER2-positive, Other, Racial Disparities|

LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis

Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre

Read More

Joel Adamich2024-02-16T07:00:39-08:00June 18th, 2023|Endocrine, Evidence, LESS|